

**Retina World Congress**  
**Macular Trials: The Good, The Bad, and The Ugly**  
**October 24, 2021**  
**Live Webinar**

---

### **Target Audience**

This activity is designed to meet the needs of retina specialists, comprehensive ophthalmologists, retina fellows and residents, and healthcare providers who are interested in applying the most recent advancements in the retinal medicine field, including emerging techniques for imaging and treatments for retinal and vitreoretinal diseases.

### **Learning Objectives**

Upon completion of the educational activity, participants should be able to:

- Describe how clinical trial results differentiate treatments based on functional, anatomic, and visual outcomes
- Sequence and combine therapies appropriately based on response to anti-VEGF and other patient-specific factors
- Evaluate innovative therapies and delivery systems based on their ability to improve durability and maintain visual outcomes
- Use imaging to diagnose patients with dry AMD and differentiate GA from other forms of AMD
- Identify patients who would be suitable candidates for gene-replacement therapy

### **Criteria for Success**

Certificates of completion will be awarded based on the participant's attendance and submission of the activity evaluation/claim credit form at <https://ivista.digitellinc.com/ivista/live/130/page/760>. **Please claim your credit by November 15, 2021.**

You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [JGoldman@akhcme.com](mailto:JGoldman@akhcme.com).



**CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.**



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and iVista Medical Education, Inc. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Physicians**

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Commercial Support**

This activity is supported by educational grants from Alcon Vision, LLC, Novartis, Regeneron Pharmaceuticals, and RegenxBio.

### **Disclosures**

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

<b>DISCLOSURES</b>		
<b>Name</b>	<b>Relationship</b>	<b>Commercial Interest</b>
<b>Ashkan Abbey, MD (faculty)</b>	Consultant	Alcon; Alimera Sciences; Allergan; Eyepoint; Genentech; Novartis; Regeneron; RegenexBio
	Independent Contractor	Allergan
	Speaker	Alcon; Allergan; Eyepoint; Genentech; Novartis; Regeneron; Spark
<b>Audina Berrocal, MD (faculty)</b>	Advisor	Aerie; Alcon; Allergan; Applied Genetic Technologies Corp; Bayer; DORC; Oculus; Phoenix; ProQR; Visunex; Zeiss
	Consultant	Alcon; DORC; Zeiss
	Speaker	Oculus
<b>Cagri Besirli, MD, PhD (faculty)</b>	Consultant	iRenix Medical; Janssen; MeiraGTx
	Executive Role	iRenix Medical
	Independent Contractor	4DMT; Janssen; MeiraGTx; Novartis; Regeneron; Spark
	Royalties	iRenix Medical; ONL Therapeutics
<b>Tarek Hassan, MD (faculty)</b>	N/A	Nothing to disclose
<b>Christine Kay, MD (faculty)</b>	Consultant	Applied Genetic Technologies Corp; Atsena Therapeutics; Spark Therapeutics
	Researcher	Alkeus; Applied Genetic Technologies Corp; Biogen; Foundation Fighting Blindness; Gyroscope; Kodiak; MeiraGTx/Janssen; Novartis; ProQR; RegenexBio; Stargazer
	Speaker	Spark Therapeutics
<b>Jorge Rocha, MD, PhD (faculty)</b>	N/A	Nothing to disclose
<b>Christina Weng, MD, MBA (faculty)</b>	Consultant	Allergan/AbbVie; Alcon; Alimera Sciences; DORC; Genentech; Novartis; Regeneron; RegenexBio
<b>Nicolas Yannuzzi, MD (faculty)</b>	Advisor	Alcon; Alimera Sciences; Genentech; Novartis; RegenexBio
<b>Dorothy Caputo, MA, BSN, RN, Vice President of Continuing Education &amp; Compliance</b>	N/A	Nothing to disclose
<b>AKH Staff and Planners</b>	N/A	Nothing to disclose
<b>iVista Staff and Planners</b>	N/A	Nothing to disclose
<b>All of the relevant financial relationships listed for these individuals have been mitigated.</b>		

#### **Disclaimer**

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

#### **Disclosure of Unlabeled Use and Investigational Product**

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.